Back

Mortality and morbidity in heart failure patients exposed to Digoxin: comprehensive data according to ejection fraction and atrial fibrillation in 41881 patients from the Swedish Heart Failure Registr

29 August 2016 (14:18 - 14:36)
Organised by:
Congress Presentation Part of: Drug therapy in heart failure Pharmacologic therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Gianluigi Savarese

Karolinska Institute, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail
State of the art in drug therapy in chronic heart failure.
Professor D. van Veldhuisen (Groningen, NL)
Slides Video
Presentation thumbnail
Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction- SpironolacTone in myocaRdial dysfUnCTion with redUced exeRcisE capacity (STRUCTURE)
Professor W. Kosmala (Wroclaw, PL)
Abstract Slides Video
Presentation thumbnail
Risk of long-term mortality associated with diuretic treatment in 17,519 heart failure outpatients was increased with 42% after adjustment for MAGGIC mortality risk predictors
Doctor P. Paren (Gothenburg, SE)
Abstract
Presentation thumbnail
Future direction for research in drug therapy.
Professor J. Teerlink (San Francisco, US)
Slides Video

Access the full session

Session thumbnail
Drug therapy in heart failure

The Event

Event poster

ESC Congress 2016

29 August 2016 14:18 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources